REGN vs. VRTX, BMY, GSK, SNY, ZTS, PFE, TAK, RPRX, BGNE, and CTLT
Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Vertex Pharmaceuticals (VRTX), Bristol-Myers Squibb (BMY), GSK (GSK), Sanofi (SNY), Zoetis (ZTS), Pfizer (PFE), Takeda Pharmaceutical (TAK), Royalty Pharma (RPRX), BeiGene (BGNE), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Regeneron Pharmaceuticals had 13 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 26 mentions for Regeneron Pharmaceuticals and 13 mentions for Vertex Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.86 beat Regeneron Pharmaceuticals' score of 0.51 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Vertex Pharmaceuticals received 58 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 66.59% of users gave Regeneron Pharmaceuticals an outperform vote.
83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 8.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Vertex Pharmaceuticals has a net margin of 36.68% compared to Regeneron Pharmaceuticals' net margin of 30.14%. Vertex Pharmaceuticals' return on equity of 21.91% beat Regeneron Pharmaceuticals' return on equity.
Regeneron Pharmaceuticals presently has a consensus price target of $977.77, indicating a potential upside of 4.28%. Vertex Pharmaceuticals has a consensus price target of $429.45, indicating a potential upside of 7.32%. Given Vertex Pharmaceuticals' higher probable upside, analysts plainly believe Vertex Pharmaceuticals is more favorable than Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.
Summary
Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Regeneron Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regeneron Pharmaceuticals Competitors List
Related Companies and Tools
